- The key vendors in the Global ACS Market 2015-2019 are AstraZeneca plc, Bristol-Myers Squibb Co., Eli Lilly and Co., GlaxoSmithKline plc and Sanofi SA
London, 11 March 2015: TechNavio, an independent tech-focused global research firm, has announced the publication of its market research report on the Global ACS Market 2015-2019. The acceptance of the treatments is expected to increase during the forecast period because of the growing public awareness of ACS. Several organizations are initiating various programs to spread awareness about ACS for the early diagnosis and treatment of the syndrome and to decrease mortality and morbidity from heart attacks. The Global ACS market is expected to grow at a CAGR of 13.24 percent during the forecast period of 2014-2019.
The market is highly competitive with the presence of a limited number of approved drugs. These drugs, including antithrombotics, anti-hypertensives, and statins, are well-established standard-of-care therapeutics, of which many are generics.
“The introduction of biologics into ACS treatment has significantly altered the ACS market, both medically and financially,” says Faisal Ghaus, Vice President of TechNavio Research.
“The use of cardiac troponins has enhanced the clinician’s ability to diagnose the disease in patients who are either at a higher risk of death or suffer from recurrent ischemic events.”
To define the market conditions in the next 3-4 years, TechNavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
